Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Advanced Proteome Therapeutics Corporation APTCF OTC

Other OTC • Healthcare • Biotechnology • CA • USD

SharesGrow Score
42/100
0/4 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Advanced Proteome Therapeutics Corporation (APTCF) is a Biotechnology company in the Healthcare sector, currently trading at $0.00. It has a SharesGrow Score of 38/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $0 against $0 equity. Total assets: $0.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Fail), Moat 28/100 (Fail), Future ?/100 (Fail), Income ?/100 (Fail).

APTCF SharesGrow Score Overview

42/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 28/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — APTCF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✗
GROWTH Fail
15/100
APTCF: +0%/yr revenue is, -88.6%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
APTCF: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
100/100
Balance sheet APTCF: Debt-to-Equity (D/E) ratio N/A, Current ratio is N/A. Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
28/100
APTCF: Gross margin is 0% (+0 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 28/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range0.0002-0.0002
Volume14.31K
Avg Volume (30D)9.99K
Market Cap$149.63K
Beta (1Y)1.41
Share Statistics
IPO Date2009-07-10
CEOBenjamin Krantz
Financial Highlights & Ratios
Analyst Forecast
Company Info
CountryCA
ExchangeOther OTC
CurrencyUSD
ISINCA0076282098

Price Chart

Track all markets on TradingView
APTCF
Advanced Proteome Therapeutics Corporation ↗  ·  Other OTC
Healthcare • Biotechnology

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message